Cargando…
Immunological Adverse Events After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients
Autologous hematopoietic stem cell transplantation (aHSCT) represents an effective treatment for systemic sclerosis (SSc), but it also can cause immunological adverse events (iAEs). Therefore, we aimed to determine the frequency of iAEs [engraftment syndrome (ES) and secondary autoimmune disorder (s...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447845/ https://www.ncbi.nlm.nih.gov/pubmed/34539659 http://dx.doi.org/10.3389/fimmu.2021.723349 |
_version_ | 1784569103880552448 |
---|---|
author | Strunz, Patrick-Pascal Froehlich, Matthias Gernert, Michael Schwaneck, Eva Christina Fleischer, Anna Pecher, Ann-Christin Tony, Hans-Peter Henes, Joerg Christoph Schmalzing, Marc |
author_facet | Strunz, Patrick-Pascal Froehlich, Matthias Gernert, Michael Schwaneck, Eva Christina Fleischer, Anna Pecher, Ann-Christin Tony, Hans-Peter Henes, Joerg Christoph Schmalzing, Marc |
author_sort | Strunz, Patrick-Pascal |
collection | PubMed |
description | Autologous hematopoietic stem cell transplantation (aHSCT) represents an effective treatment for systemic sclerosis (SSc), but it also can cause immunological adverse events (iAEs). Therefore, we aimed to determine the frequency of iAEs [engraftment syndrome (ES) and secondary autoimmune disorder (sAD)] and to identify potential risk factors for their development in a retrospective analysis on 22 patients similarly transplanted due to SSc. While nine patients (41%) suffered from ESs, seven sADs occurred in six patients (27%). Patients who developed ES were older in our cohort (52.45 vs. 42.58 years, p = .0433, Cohen’s d = 0.86), and cardiac involvement by SSc was associated with development of ES (OR = 40.11, p = .0017). Patients with manifestation of sAD had a higher modified Rodnan skin score (mRSS) reduction after aHSCT (90.50% vs. 60.00%, p = .0064, r = .65). Thus, IAEs are common after aHSCT for SSc and can occur in different stages during and after aHSCT with characteristic clinical manifestations. Good cutaneous response after aHSCT might be considered as a risk factor for sAD, and higher age at aHSCT and cardiac involvement might be considered as risk factors for the development of ES. |
format | Online Article Text |
id | pubmed-8447845 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84478452021-09-18 Immunological Adverse Events After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients Strunz, Patrick-Pascal Froehlich, Matthias Gernert, Michael Schwaneck, Eva Christina Fleischer, Anna Pecher, Ann-Christin Tony, Hans-Peter Henes, Joerg Christoph Schmalzing, Marc Front Immunol Immunology Autologous hematopoietic stem cell transplantation (aHSCT) represents an effective treatment for systemic sclerosis (SSc), but it also can cause immunological adverse events (iAEs). Therefore, we aimed to determine the frequency of iAEs [engraftment syndrome (ES) and secondary autoimmune disorder (sAD)] and to identify potential risk factors for their development in a retrospective analysis on 22 patients similarly transplanted due to SSc. While nine patients (41%) suffered from ESs, seven sADs occurred in six patients (27%). Patients who developed ES were older in our cohort (52.45 vs. 42.58 years, p = .0433, Cohen’s d = 0.86), and cardiac involvement by SSc was associated with development of ES (OR = 40.11, p = .0017). Patients with manifestation of sAD had a higher modified Rodnan skin score (mRSS) reduction after aHSCT (90.50% vs. 60.00%, p = .0064, r = .65). Thus, IAEs are common after aHSCT for SSc and can occur in different stages during and after aHSCT with characteristic clinical manifestations. Good cutaneous response after aHSCT might be considered as a risk factor for sAD, and higher age at aHSCT and cardiac involvement might be considered as risk factors for the development of ES. Frontiers Media S.A. 2021-09-03 /pmc/articles/PMC8447845/ /pubmed/34539659 http://dx.doi.org/10.3389/fimmu.2021.723349 Text en Copyright © 2021 Strunz, Froehlich, Gernert, Schwaneck, Fleischer, Pecher, Tony, Henes and Schmalzing https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Strunz, Patrick-Pascal Froehlich, Matthias Gernert, Michael Schwaneck, Eva Christina Fleischer, Anna Pecher, Ann-Christin Tony, Hans-Peter Henes, Joerg Christoph Schmalzing, Marc Immunological Adverse Events After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients |
title | Immunological Adverse Events After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients |
title_full | Immunological Adverse Events After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients |
title_fullStr | Immunological Adverse Events After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients |
title_full_unstemmed | Immunological Adverse Events After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients |
title_short | Immunological Adverse Events After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients |
title_sort | immunological adverse events after autologous hematopoietic stem cell transplantation in systemic sclerosis patients |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447845/ https://www.ncbi.nlm.nih.gov/pubmed/34539659 http://dx.doi.org/10.3389/fimmu.2021.723349 |
work_keys_str_mv | AT strunzpatrickpascal immunologicaladverseeventsafterautologoushematopoieticstemcelltransplantationinsystemicsclerosispatients AT froehlichmatthias immunologicaladverseeventsafterautologoushematopoieticstemcelltransplantationinsystemicsclerosispatients AT gernertmichael immunologicaladverseeventsafterautologoushematopoieticstemcelltransplantationinsystemicsclerosispatients AT schwaneckevachristina immunologicaladverseeventsafterautologoushematopoieticstemcelltransplantationinsystemicsclerosispatients AT fleischeranna immunologicaladverseeventsafterautologoushematopoieticstemcelltransplantationinsystemicsclerosispatients AT pecherannchristin immunologicaladverseeventsafterautologoushematopoieticstemcelltransplantationinsystemicsclerosispatients AT tonyhanspeter immunologicaladverseeventsafterautologoushematopoieticstemcelltransplantationinsystemicsclerosispatients AT henesjoergchristoph immunologicaladverseeventsafterautologoushematopoieticstemcelltransplantationinsystemicsclerosispatients AT schmalzingmarc immunologicaladverseeventsafterautologoushematopoieticstemcelltransplantationinsystemicsclerosispatients |